Alnylam Pharmaceuticals (Nasdaq: ALNY) announced it will present clinical and real-world data from its transthyretin-mediated amyloidosis (ATTR) and hypertension programs ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE